- ISIN DE000A11QVV0
- Country Deutschland
Latest Reports
News Functions
Additional Functions
26 March 2024
Heidelberg Pharma AG
Annual financial report 2022/2023
Heidelberg Pharma AG
Jahresfinanzbericht 2022/2023
12 October 2023
Heidelberg Pharma AG
Q3 statement / Q3 financial report 2022/2023
13 July 2023
Heidelberg Pharma AG
Half-yearly financial report 2022/2023
19 April 2023
Heidelberg Pharma AG
Q1 statement / Q1 financial report 2022/2023
28 March 2023
Heidelberg Pharma AG
Annual financial report 2021/2022
24 March 2023
Heidelberg Pharma AG
Jahresfinanzbericht 2021/2022
13 October 2022
Heidelberg Pharma AG
Q3 statement / Q3 financial report 2021/2022
12 July 2022
Heidelberg Pharma AG
Half-yearly financial report 2021/2022
28 April 2022
Heidelberg Pharma AG
Q1 statement / Q1 financial report 2021/2022
31 March 2022
Heidelberg Pharma AG
Jahresfinanzbericht 2020/2021
29 March 2022
Heidelberg Pharma AG
Annual financial report 2020/2021
11 October 2021
Heidelberg Pharma AG
Q3 statement / Q3 financial report 2020/2021
19 July 2021
Heidelberg Pharma AG
Q1 statement / Q1 financial report 2020/2021
Heidelberg Pharma AG
Half-yearly financial report 2020/2021
Heidelberg Pharma AG
Annual financial report 2019/2020
13 October 2020
Heidelberg Pharma AG
Q3 statement / Q3 financial report 2019/2020
9 July 2020
Heidelberg Pharma AG
Half-yearly financial report 2019/2020
Latest News
News Functions
Additional Functions
17 April 2024
Heidelberg Pharma AG
Heidelberg Pharma AG: Walter Miller, buy
5 April 2024
Heidelberg Pharma AG
Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
27 March 2024
Heidelberg Pharma AG
Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
26 March 2024
Heidelberg Pharma AG
Heidelberg Pharma AG: Dr. Georg F. Baur, buy
25 March 2024
Heidelberg Pharma AG
Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
19 March 2024
Heidelberg Pharma AG
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty